Zeng Wei-Nan, Zhang Yun, Wang Duan, Zeng Yi-Ping, Yang Hao, Li Juan, Zhou Cheng-Pei, Liu Jun-Li, Yang Qing-Jun, Deng Zhong-Liang, Zhou Zong-Ke
Orthopedic Research Institution, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Department of Orthopedics, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China.
Am J Sports Med. 2021 Aug;49(10):2795-2809. doi: 10.1177/03635465211023183. Epub 2021 Jul 2.
In this study, we investigated the in vitro and in vivo chondrogenic capacity of kartogenin (KGN)-enhanced bone marrow-derived mesenchymal stem cells (BMSCs) for cartilage regeneration.
To determine (1) whether functionalized nanographene oxide (NGO) can effectively deliver KGN into BMSCs and (2) whether KGN would enhance BMSCs during chondrogenesis in vitro and in vivo in an animal model.
Controlled laboratory study.
Functionalized NGO with line chain amine-terminated polyethylene glycol (PEG) and branched polyethylenimine (BPEI) were used to synthesize biocompatible NGO-PEG-BPEI (PPG) and for loading hydrophobic KGN molecules noncovalently via π-π stacking and hydrophobic interactions (PPG-KGN). Then, PPG-KGN was used for the intracellular delivery of hydrophobic KGN by simple mixing and co-incubation with BMSCs to acquire KGN-enhanced BMSCs. The chondrogenic efficacy of KGN-enhanced BMSCs was evaluated in vitro. In vivo, osteoarthritis (OA) was induced by anterior cruciate ligament transection in rats. A total of 5 groups were established: normal (OA treated with nothing), phosphate-buffered saline (PBS; intra-articular injection of PBS), PPG-KGN (intra-articular injection of PPG-KGN), BMSCs (intra-articular injection of BMSCs), and BMSCs + PPG-KGN (intra-articular injection of PPG-KGN-preconditioned BMSCs). At 6 and 9 weeks after the surgical induction of OA, the rats received intra-articular injections of PPG-KGN, BMSCs, or KGN-enhanced BMSCs. At 14 weeks after the surgical induction of OA, radiographic and behavioral evaluations as well as histological analysis of the knee joints were performed.
The in vitro study showed that PPG could be rapidly uptaken in the first 4 hours after incubation, reaching saturation at 12 hours and accumulating in the lysosome and cytoplasm of BMSCs. Thus, PPG-KGN could enhance the efficiency of the intracellular delivery of KGN, which showed a remarkably high chondrogenic differentiation capacity of BMSCs. When applied to an OA model of cartilage injuries in rats, PPG-KGN-preconditioned BMSCs contributed to protection from joint space narrowing, pathological mineralization, OA development, and OA-induced pain, as well as improved tissue regeneration, as evidenced by radiographic, weightbearing, and histological findings.
Our results demonstrate that KGN-enhanced BMSCs showed markedly improved capacities for chondrogenesis and articular cartilage repair. We believe that this work demonstrates that a multifunctional nanoparticle-based drug delivery system could be beneficial for stem cell therapy. Our results present an opportunity to reverse the symptoms and pathophysiology of OA.
The intracellular delivery of KGN to produce BMSCs with enhanced chondrogenic potential may offer a new approach for the treatment of OA.
在本研究中,我们调查了卡托金(KGN)增强的骨髓间充质干细胞(BMSC)在体外和体内的软骨生成能力,用于软骨再生。
确定(1)功能化氧化石墨烯(NGO)是否能有效地将KGN递送至BMSC,以及(2)KGN在体外软骨生成过程中以及在动物模型体内是否会增强BMSC。
对照实验室研究。
使用带有直链胺端聚乙二醇(PEG)和支链聚乙烯亚胺(BPEI)的功能化NGO合成生物相容性NGO-PEG-BPEI(PPG),并通过π-π堆积和疏水相互作用非共价加载疏水性KGN分子(PPG-KGN)。然后,通过简单混合并与BMSC共同孵育,使用PPG-KGN进行疏水性KGN的细胞内递送,以获得KGN增强的BMSC。在体外评估KGN增强的BMSC的软骨生成功效。在体内,通过切断大鼠前交叉韧带诱导骨关节炎(OA)。总共建立了5组:正常组(未接受任何处理的OA组)、磷酸盐缓冲盐水(PBS;关节内注射PBS)、PPG-KGN组(关节内注射PPG-KGN)、BMSC组(关节内注射BMSC)和BMSC + PPG-KGN组(关节内注射经PPG-KGN预处理的BMSC)。在手术诱导OA后的6周和9周,大鼠接受关节内注射PPG-KGN、BMSC或KGN增强的BMSC。在手术诱导OA后的14周,进行影像学和行为评估以及膝关节的组织学分析。
体外研究表明,PPG在孵育后的前4小时可被快速摄取,12小时达到饱和,并在BMSC的溶酶体和细胞质中积累。因此,PPG-KGN可提高KGN的细胞内递送效率,这表明BMSC具有显著高的软骨生成分化能力。当应用于大鼠软骨损伤的OA模型时,经PPG-KGN预处理的BMSC有助于防止关节间隙变窄、病理性矿化、OA发展和OA诱导的疼痛,以及改善组织再生,影像学、负重和组织学结果均证明了这一点。
我们的结果表明,KGN增强的BMSC显示出明显改善的软骨生成和关节软骨修复能力。我们认为这项工作表明基于多功能纳米颗粒药物递送系统可能有利于干细胞治疗。我们的结果为逆转OA的症状和病理生理学提供了机会。
将KGN进行细胞内递送以产生具有增强软骨生成潜力的BMSC可能为OA的治疗提供一种新方法。